PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, today announced that it has been named Large Company of the Year for 2005 by the New Jersey Technology Council (NJTC). Pharmacopeia was announced as the winner during the annual NJTC Gala Awards on Friday, November 4, 2005.
The NJTC’s annual awards event recognizes outstanding New Jersey-based companies in myriad technology sectors including IT, life sciences, communications, and electronics. Awards given at the NJTC Gala include Large Company of the Year, Growth Company of the Year, and Early-Stage Company of the Year, among others. Founded in 1996, the Awards Gala is hosted by the NJTC with support from several key sponsors.
“As a two-time winner, we are especially honored to receive this prestigious award from the New Jersey Technology Council,” said Les Browne, Ph.D., Pharmacopeia’s President and Chief Executive Officer. “This recognition comes at a time at which we have established Pharmacopeia as a leading therapeutic product business with a robust partnered product pipeline and a growing wholly-owned portfolio. We are pleased to be associated with NJTC and the work it is doing to promote business in the state of New Jersey.”
Pharmacopeia, which was founded in New Jersey in 1993, is presently advancing multiple internal therapeutic programs - focused primarily on immunobiology and immunological diseases - towards validation in clinical trials. The company’s most advanced internal programs include JAK3 inhibitors designed to produce novel therapeutics to help patients suffering from diseases like psoriasis, multiple sclerosis and transplant rejection.
ABOUT THE NJTC
The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC’s more than 1,100 member companies work together to support their own enterprises while advancing New Jersey’s status as a leading technology center in the United States. For more information on the NJTC, visit http://www.njtc.org.
ABOUT PHARMACOPEIA
Pharmacopeia creates and delivers novel therapeutics to address significant medical needs. Using proprietary technologies and processes, Pharmacopeia discovers and develops novel drug candidates to advance internally as well as with strategic partners. The company is advancing multiple internal programs - focused primarily on immunobiology and immunological diseases - to validation in clinical trials. Pharmacopeia’s later stage portfolio currently comprises multiple partnered programs that have been advanced into human clinical trials with further programs in late- stage pre-clinical development. Beyond these, the company has several internal programs in advanced pre-clinical optimization and multiple partnered programs in discovery that are expected to drive the company’s clinical portfolio in the future.
Contact: Michio Soga Executive Vice President & Chief Financial Officer Pharmacopeia Drug Discovery, Inc. (609) 452-3643 irreq@pcop.com Tim Brons (media) Vida Communication (415) 675-7402 tbrons@vidacommunication.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia’s strategic plans, Pharmacopeia’s intentions regarding the establishment and continuation of drug discovery collaborations with leading pharmaceutical and biotechnology organizations, in particular, the continuation and funding level of such continuation of Pharmacopeia’s existing collaborations with Schering-Plough and N.V. Organon, Pharmacopeia’s ability to build its pipeline of novel drug candidates, through its own internally-funded drug discovery programs, third party collaborations and in- licensing, Pharmacopeia’s ability to raise additional capital, Pharmacopeia’s anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia’s expectations concerning the development priorities of its collaborators and their ability to successfully develop compounds, Pharmacopeia’s expectations concerning the legal protections afforded by U.S. and international patent law, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its Report on Form 10-Q filed on November 4, 2005, its Report on Form 10-K filed on March 23, 2005 and subsequent filings under the Securities and Exchange Act of 1934. All forward- looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Pharmacopeia
CONTACT: Michio Soga, Executive Vice President & Chief Financial Officer,Pharmacopeia Drug Discovery, Inc., +1-609-452-3643, irreq@pcop.com; or TimBrons (media), Vida Communication, +1-415-675-7402,tbrons@vidacommunication.com
